Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 94

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

p53/MDM2 signaling pathway in aging, senescence and tumorigenesis

Huang, Youyi, Che, Xiaofang, Wang, Peter W., Qu, Xiujuan · 2024 · Seminars in Cancer Biology

Abstract

A wealth of evidence has emerged that there is an association between aging, senescence and tumorigenesis. Senescence, a biological process by which cells cease to divide and enter a status of permanent cell cycle arrest, contributes to aging and aging-related diseases, including cancer. Aging populations have the higher incidence of cancer due to a lifetime of exposure to cancer-causing agents, reduction of repairing DNA damage, accumulated genetic mutations, and decreased immune system efficiency. Cancer patients undergoing cytotoxic therapies, such as chemotherapy and radiotherapy, accelerate aging. There is growing evidence that p53/MDM2 (murine double minute 2) axis is critically involved in regulation of aging, senescence and oncogenesis. Therefore, in this review, we describe the functions and mechanisms of p53/MDM2-mediated senescence, aging and carcinogenesis. Moreover, we highlight the small molecular inhibitors, natural compounds and PROTACs (proteolysis targeting chimeras) that target p53/MDM2 pathway to influence aging and cancer. Modification of p53/MDM2 could be a potential strategy for treatment of aging, senescence and tumorigenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2024.05.001

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 163

  1. Martin, 1996, Genetic analysis of ageing: role of oxidative damage and environmental stresses, Nat. Genet, 13, 25, 10.1038/ng0596-25 · DOI · Paper page
  2. Partridge, 2002, Mechanisms of ageing: public or private?, Nat. Rev. Genet, 3, 165, 10.1038/nrg753 · DOI · Paper page
  3. Melzer, 2020, The genetics of human ageing, Nat. Rev. Genet, 21, 88, 10.1038/s41576-019-0183-6 · DOI · Paper page
  4. Vitale, 2013, Oxidative stress and the ageing endocrine system, Nat. Rev. Endocrinol., 9, 228, 10.1038/nrendo.2013.29 · DOI · Paper page
  5. Benz, 2008, Ageing, oxidative stress and cancer: paradigms in parallax, Nat. Rev. Cancer, 8, 875, 10.1038/nrc2522 · DOI · Paper page
  6. Zhang, 2020, The ageing epigenome and its rejuvenation, Nat. Rev. Mol. Cell Biol., 21, 137, 10.1038/s41580-019-0204-5 · DOI · Paper page
  7. Ogrodnik, 2023, The meaning of adaptation in aging: insights from cellular senescence, epigenetic clocks and stem cell alterations, Nat. Aging, 3, 766, 10.1038/s43587-023-00447-5 · DOI
  8. Bitencourt, 2024, Subcellular structure, heterogeneity, and plasticity of senescent cells, Aging Cell, 10.1111/acel.14154 · DOI
  9. Pizzul, 2023, The multistep path to replicative senescence onset: zooming on triggering and inhibitory events at telomeric DNA, Front Cell Dev. Biol., 11, 10.3389/fcell.2023.1250264 · DOI
  10. Larsson, 2011, Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence, Semin Cancer Biol., 21, 367, 10.1016/j.semcancer.2011.10.005 · DOI
  11. Wang, 2022, Exploiting senescence for the treatment of cancer, Nat. Rev. Cancer, 22, 340, 10.1038/s41568-022-00450-9 · DOI · Paper page
  12. Guo, 2022, Aging and aging-related diseases: from molecular mechanisms to interventions and treatments, Signal Transduct. Target Ther., 7, 391, 10.1038/s41392-022-01251-0 · DOI · Paper page
  13. Lieber, 2004, Ageing, repetitive genomes and DNA damage, Nat. Rev. Mol. Cell Biol., 5, 69, 10.1038/nrm1281 · DOI
  14. Muss, 2020, p16 a biomarker of aging and tolerance for cancer therapy, Transl. Cancer Res, 9, 5732, 10.21037/tcr.2020.03.39 · DOI
  15. LaPak, 2014, The molecular balancing act of p16(INK4a) in cancer and aging, Mol. Cancer Res, 12, 167, 10.1158/1541-7786.MCR-13-0350 · DOI · Paper page
  16. Kennedy, 2014, RB and lamins in cell cycle regulation and aging, Adv. Exp. Med Biol., 773, 127, 10.1007/978-1-4899-8032-8_6 · DOI
  17. Fu, 2023, Targeting mTOR for anti-aging and anti-cancer therapy, Molecules, 28, 10.3390/molecules28073157 · DOI
  18. Ou, 2018, DNA damage responses and p53 in the aging process, Blood, 131, 488, 10.1182/blood-2017-07-746396 · DOI · Paper page
  19. Yi, 2010, SIRT1 and p53, effect on cancer, senescence and beyond, Biochim Biophys. Acta, 1804, 1684, 10.1016/j.bbapap.2010.05.002 · DOI · Paper page
  20. Wu, 2018, Relevance of the p53-MDM2 axis to aging, Cell Death Differ., 25, 169, 10.1038/cdd.2017.187 · DOI · Paper page
  21. Vazquez, 2008, The genetics of the p53 pathway, apoptosis and cancer therapy, Nat. Rev. Drug Discov., 7, 979, 10.1038/nrd2656 · DOI · Paper page
  22. Chang, 1995, Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein, J. Biol. Chem., 270, 25014, 10.1074/jbc.270.42.25014 · DOI
  23. Liu, 2003, The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein, J. Biol. Chem., 278, 17557, 10.1074/jbc.M210696200 · DOI
  24. Scoumanne, 2005, Structural basis for gene activation by p53 family members, Cancer Biol. Ther., 4, 1178, 10.4161/cbt.4.11.2254 · DOI
  25. Silva, 2013, Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor, Biosci. Rep., 33, 10.1042/BSR20130065 · DOI
  26. Dikic, 2023, An expanded lexicon for the ubiquitin code, Nat. Rev. Mol. Cell Biol., 24, 273, 10.1038/s41580-022-00543-1 · DOI · Paper page
  27. Popovic, 2014, Ubiquitination in disease pathogenesis and treatment, Nat. Med, 20, 1242, 10.1038/nm.3739 · DOI · Paper page
  28. Zheng, 2023, Elucidating the role of ubiquitination and deubiquitination in osteoarthritis progression, Front Immunol., 14, 1217466, 10.3389/fimmu.2023.1217466 · DOI
  29. Liu, 2022, Targeting matrix metalloproteinases by E3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy, Semin Cancer Biol., 86, 259, 10.1016/j.semcancer.2022.06.004 · DOI
  30. Wang, 2022, Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy, Semin Cancer Biol., 87, 84, 10.1016/j.semcancer.2022.11.002 · DOI
  31. Wang, 2014, Roles of F-box proteins in cancer, Nat. Rev. Cancer, 14, 233, 10.1038/nrc3700 · DOI · Paper page
  32. Senft, 2018, Ubiquitin ligases in oncogenic transformation and cancer therapy, Nat. Rev. Cancer, 18, 69, 10.1038/nrc.2017.105 · DOI · Paper page
  33. Dobbelstein, 2020, Mdm2: Open questions, Cancer Sci., 111, 2203, 10.1111/cas.14433 · DOI
  34. Tan, 2017, Anatomy of Mdm2 and Mdm4 in evolution, J. Mol. Cell Biol., 9, 3, 10.1093/jmcb/mjx002 · DOI · Paper page
  35. Lindstrom, 2007, Putting a finger on growth surveillance: insight into MDM2 zinc finger-ribosomal protein interactions, Cell Cycle, 6, 434, 10.4161/cc.6.4.3861 · DOI
  36. Mendoza, 2014, The MDM2 gene family, Biomol. Concepts, 5, 9, 10.1515/bmc-2013-0027 · DOI
  37. O'Keefe, 2003, Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination, Mol. Cell Biol., 23, 6396, 10.1128/MCB.23.18.6396-6405.2003 · DOI
  38. Moqri, 2023, Biomarkers of aging for the identification and evaluation of longevity interventions, Cell, 186, 3758, 10.1016/j.cell.2023.08.003 · DOI · Paper page
  39. Zhavoronkov, 2019, Deep biomarkers of aging and longevity: from research to applications, Aging (Albany NY), 11, 10771, 10.18632/aging.102475 · DOI
  40. de Magalhaes, 2024, Distinguishing between driver and passenger mechanisms of aging, Nat. Genet, 56, 204, 10.1038/s41588-023-01627-0 · DOI
  41. Lin, 2024, MDMX in Cancer: A Partner of p53 and a p53-Independent Effector, Biologics, 18, 61
  42. Aguilar, 2022, Therapeutic strategies to activate p53, Pharm. (Basel), 16
  43. Dumble, 2004, Insights into aging obtained from p53 mutant mouse models, Ann. N. Y Acad. Sci., 1019, 171, 10.1196/annals.1297.027 · DOI
  44. Gentry, 2005, Complicating the role of p53 in aging, Aging Cell, 4, 157, 10.1111/j.1474-9726.2005.00154.x · DOI
  45. Garcia-Cao, 2002, Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally, EMBO J., 21, 6225, 10.1093/emboj/cdf595 · DOI · Paper page
  46. Liu, 2010, Puma is required for p53-induced depletion of adult stem cells, Nat. Cell Biol., 12, 993, 10.1038/ncb2100 · DOI
  47. Chao, 2006, Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression, EMBO J., 25, 2615
  48. Li, 2016, Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging, Oncotarget, 7, 11838, 10.18632/oncotarget.7864 · DOI
  49. Maor-Nof, 2021, p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR), Cell, 184, 689, 10.1016/j.cell.2020.12.025 · DOI · Paper page
  50. Morganti, 2022, NPM1 ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by p53 loss, EMBO Rep., 23, 10.15252/embr.202154262 · DOI
  51. Lessel, 2017, Dysfunction of the MDM2/p53 axis is linked to premature aging, J. Clin. Invest, 127, 3598, 10.1172/JCI92171 · DOI
  52. Itahana, 2007, Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation, Cancer Cell, 12, 355, 10.1016/j.ccr.2007.09.007 · DOI · Paper page
  53. Pant, 2016, Distinct downstream targets manifest p53-dependent pathologies in mice, Oncogene, 35, 5713, 10.1038/onc.2016.111 · DOI
  54. Pant, 2013, The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity, Genes Dev., 27, 1857, 10.1101/gad.227249.113 · DOI
  55. Tollini, 2014, Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage, Cancer Cell, 26, 235, 10.1016/j.ccr.2014.06.006 · DOI
  56. Soussi, 2007, Shaping genetic alterations in human cancer: the p53 mutation paradigm, Cancer Cell, 12, 303, 10.1016/j.ccr.2007.10.001 · DOI · Paper page
  57. Figueiredo, 2006, Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation, J. Med Genet, 43, 91, 10.1136/jmg.2004.030551 · DOI · Paper page
  58. Attardi, 2005, Probing p53 biological functions through the use of genetically engineered mouse models, Mutat. Res, 576, 4, 10.1016/j.mrfmmm.2004.08.022 · DOI
  59. Lavigueur, 1989, High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene, Mol. Cell Biol., 9, 3982
  60. Lee, 1994, Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice, Oncogene, 9, 3731
  61. Harvey, 1995, A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice, Nat. Genet, 9, 305, 10.1038/ng0395-305 · DOI · Paper page
  62. Li, 1997, neu/ERBB2 cooperates with p53–172 H during mammary tumorigenesis in transgenic mice, Mol. Cell Biol., 17, 3155, 10.1128/MCB.17.6.3155 · DOI
  63. Klein, 2000, Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant, Oncogene, 19, 5329, 10.1038/sj.onc.1203941 · DOI
  64. Duan, 2002, Lung-specific expression of human mutant p53–273 H is associated with a high frequency of lung adenocarcinoma in transgenic mice, Oncogene, 21, 7831, 10.1038/sj.onc.1205909 · DOI
  65. Yin, 1998, Control of mouse hepatocyte proliferation and ploidy by p53 and p53ser246 mutation in vivo, Hepatology, 27, 73, 10.1002/hep.510270113 · DOI
  66. Ghebranious, 1998, The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice, Hepatology, 27, 967, 10.1002/hep.510270411 · DOI
  67. Donehower, 1992, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours, Nature, 356, 215, 10.1038/356215a0 · DOI · Paper page
  68. Jacks, 1994, Tumor spectrum analysis in p53-mutant mice, Curr. Biol., 4, 1, 10.1016/S0960-9822(00)00002-6 · DOI · Paper page
  69. Purdie, 1994, Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene, Oncogene, 9, 603
  70. Tsukada, 1993, Enhanced proliferative potential in culture of cells from p53-deficient mice, Oncogene, 8, 3313
  71. Armstrong, 1995, High-frequency developmental abnormalities in p53-deficient mice, Curr. Biol., 5, 931, 10.1016/S0960-9822(95)00183-7 · DOI · Paper page
  72. Sah, 1995, A subset of p53-deficient embryos exhibit exencephaly, Nat. Genet, 10, 175, 10.1038/ng0695-175 · DOI · Paper page
  73. Venkatachalam, 1998, Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation, EMBO J., 17, 4657, 10.1093/emboj/17.16.4657 · DOI · Paper page
  74. Venkatachalam, 2001, Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing, Toxicol. Pathol., 29, 147, 10.1080/019262301753178555 · DOI
  75. Harvey, 1993, Genetic background alters the spectrum of tumors that develop in p53-deficient mice, FASEB J., 7, 938, 10.1096/fasebj.7.10.8344491 · DOI · Paper page
  76. Kuperwasser, 2000, Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome, Am. J. Pathol., 157, 2151, 10.1016/S0002-9440(10)64853-5 · DOI · Paper page
  77. Jonkers, 2001, Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer, Nat. Genet, 29, 418, 10.1038/ng747 · DOI · Paper page
  78. Xu, 2001, Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis, Nat. Genet, 28, 266, 10.1038/90108 · DOI · Paper page
  79. Xu, 1999, Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation, Nat. Genet, 22, 37, 10.1038/8743 · DOI · Paper page
  80. Blyth, 1995, Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss, Oncogene, 10, 1717
  81. Elson, 1995, The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice, Oncogene, 11, 181
  82. Curtis, 1997, The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice, Oncogene, 15, 2975, 10.1038/sj.onc.1201467 · doi:10.1038/sj.onc.1201467
  83. Brodie, 2001, Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis, Oncogene, 20, 1445, 10.1038/sj.onc.1204222 · DOI
  84. Donehower, 1995, Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability, Genes Dev., 9, 882, 10.1101/gad.9.7.882 · DOI · Paper page
  85. Hundley, 1997, Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53, Mol. Cell Biol., 17, 723, 10.1128/MCB.17.2.723 · DOI
  86. Marin, 1994, Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis, Oncogene, 9, 3107
  87. Harvey, 1995, Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin, Cancer Res, 55, 1146
  88. Williams, 1994, Cooperative tumorigenic effects of germline mutations in Rb and p53, Nat. Genet, 7, 480, 10.1038/ng0894-480 · DOI · Paper page
  89. Knudson, 2001, Bax accelerates tumorigenesis in p53-deficient mice, Cancer Res, 61, 659
  90. Hosokawa, 2001, In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53, Transgenic Res, 10, 471, 10.1023/A:1012064911751 · doi:10.1023/a:1012064911751
  91. Cichowski, 1999, Mouse models of tumor development in neurofibromatosis type 1, Science, 286, 2172, 10.1126/science.286.5447.2172 · DOI · Paper page
  92. Reilly, 2000, Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects, Nat. Genet, 26, 109, 10.1038/79075 · DOI · Paper page
  93. McClatchey, 1998, Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors, Genes Dev., 12, 1121, 10.1101/gad.12.8.1121 · DOI · Paper page
  94. Halberg, 2000, Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers, Proc. Natl. Acad. Sci. USA, 97, 3461, 10.1073/pnas.97.7.3461 · DOI
  95. Wetmore, 2001, Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched, Cancer Res, 61, 513
  96. Artandi, 2000, Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice, Nature, 406, 641, 10.1038/35020592 · DOI · Paper page
  97. Cornelissen, 2019, Exogenous ERalpha Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice, J. Mammary Gland Biol. Neoplasia, 24, 305, 10.1007/s10911-019-09437-z · DOI
  98. Reuss, 2023, Simultaneous Nbs1 and p53 inactivation in neural progenitors triggers high-grade gliomas, Neuropathol. Appl. Neurobiol., 49, 10.1111/nan.12915 · DOI
  99. Jones, 1998, Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis, Proc. Natl. Acad. Sci. USA, 95, 15608, 10.1073/pnas.95.26.15608 · DOI · Paper page
  100. Carr, 2016, Mdm2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis, Cell Rep., 16, 2618, 10.1016/j.celrep.2016.08.014 · DOI
  101. Macias, 2010, An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction, Cancer Cell, 18, 231, 10.1016/j.ccr.2010.08.007 · DOI · Paper page
  102. Meng, 2015, Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways, Oncogene, 34, 5709, 10.1038/onc.2015.39 · DOI
  103. Liu, 2017, Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis, Oncogene, 36, 1374, 10.1038/onc.2016.301 · DOI
  104. Pan, 2011, The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression, PLoS One, 6, 10.1371/journal.pone.0021625 · DOI
  105. Cheng, 2010, Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis, Cancer Res, 70, 7684, 10.1158/0008-5472.CAN-09-3231 · DOI
  106. Han, 2022, PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective, Acta Mater. Med, 1, 244
  107. Bhatia, 2023, Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer, Curr. Med Chem., 30, 3668, 10.2174/0929867330666221114103924 · DOI
  108. Alaseem, 2023, Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens, Saudi Pharm. J., 31, 10.1016/j.jsps.2023.101790 · DOI
  109. Konopleva, 2020, MDM2 inhibition: an important step forward in cancer therapy, Leukemia, 34, 2858, 10.1038/s41375-020-0949-z · DOI · Paper page
  110. Rusiecki, 2019, MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present), Recent Pat. Anticancer Drug Discov., 14, 324, 10.2174/1574892814666191022163540 · DOI
  111. Cha, 2005, Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth, Cancer Res, 65, 2287, 10.1158/0008-5472.CAN-04-3250 · DOI · Paper page
  112. Rong, 2009, Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53, Cancer Lett., 284, 102, 10.1016/j.canlet.2009.04.011 · DOI
  113. Lai, 2012, Aciculatin induces p53-dependent apoptosis via MDM2 depletion in human cancer cells in vitro and in vivo, PLoS One, 7, 10.1371/journal.pone.0042192 · DOI
  114. Jia, 2023, Ganoderic Acid A and Its Amide Derivatives as Potential Anti-Cancer Agents by Regulating the p53-MDM2 Pathway: Synthesis and Biological Evaluation, Molecules, 28, 10.3390/molecules28052374 · DOI
  115. Gao, 2020, Chemopreventive Agent 3,3′-Diindolylmethane Inhibits MDM2 in Colorectal Cancer Cells, Int J. Mol. Sci., 21, 10.3390/ijms21134642 · DOI
  116. Park, 2020, The Antiproliferative Activity of Oxypeucedanin via Induction of G(2)/M Phase Cell Cycle Arrest and p53-Dependent MDM2/p21 Expression in Human Hepatoma Cells, Molecules, 25
  117. Tin, 2014, Essential role of the cancer stem/progenitor cell marker nucleostemin for indole-3-carbinol anti-proliferative responsiveness in human breast cancer cells, BMC Biol., 12, 72, 10.1186/s12915-014-0072-6 · DOI
  118. Li, 2007, Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway, Cancer Res, 67, 1988, 10.1158/0008-5472.CAN-06-3066 · DOI · Paper page
  119. Gao, 2020, Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways, Aging (Albany NY), 12, 6240, 10.18632/aging.103019 · DOI
  120. Li, 2005, Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels, Cancer Res, 65, 8200, 10.1158/0008-5472.CAN-05-1302 · DOI
  121. Yu, 2020, Resveratrol promotes osteogenesis and alleviates osteoporosis by inhibiting p53, Aging (Albany NY), 12, 10359, 10.18632/aging.103262 · DOI
  122. Bekes, 2022, PROTAC targeted protein degraders: the past is prologue, Nat. Rev. Drug Discov., 21, 181, 10.1038/s41573-021-00371-6 · DOI · Paper page
  123. Liu, 2022, Targeting micro-environmental pathways by PROTACs as a therapeutic strategy, Semin Cancer Biol., 86, 269, 10.1016/j.semcancer.2022.07.001 · DOI
  124. Kelm, 2023, PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy, Mol. Cancer, 22, 62, 10.1186/s12943-022-01707-5 · DOI
  125. Choudhary, 2023, Target protein degradation by protacs: A budding cancer treatment strategy, Pharm. Ther., 250, 10.1016/j.pharmthera.2023.108525 · DOI
  126. Inuzuka, 2022, PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives, Acta Mater. Med, 1, 24
  127. Wang, 2020, PhotoPROTACs: A Novel Biotechnology for Cancer Treatment, Trends Cell Biol., 30, 749, 10.1016/j.tcb.2020.08.003 · DOI
  128. Ahmad, 2023, Recent Advances in PROTAC-Based Antiviral Strategies, Vaccin. (Basel), 11
  129. He, 2024, Progress in the controllability technology of PROTAC, Eur. J. Med Chem., 265, 10.1016/j.ejmech.2023.116096 · DOI
  130. Chen, 2023, Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity, J. Med Chem., 66, 8428, 10.1021/acs.jmedchem.3c00302 · DOI
  131. Rovers, 2023, Methods for computer-assisted PROTAC design, Methods Enzym., 690, 311, 10.1016/bs.mie.2023.06.020 · DOI
  132. Wang, 2021, Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries, Eur. J. Med Chem., 219, 10.1016/j.ejmech.2021.113425 · DOI · Paper page
  133. Wurz, 2019, Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors, J. Med Chem., 62, 445, 10.1021/acs.jmedchem.8b01945 · DOI
  134. Yang, 2023, Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2, J. Adv. Res, 45, 59, 10.1016/j.jare.2022.05.009 · DOI
  135. Adams, 2023, Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer, Cancer Discov., 13, 1210, 10.1158/2159-8290.CD-22-1131 · DOI
  136. Peuget, 2023, MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation, Cancer Discov., 13, 1043, 10.1158/2159-8290.CD-23-0229 · DOI
  137. Wang, 2023, Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer, Bioorg. Chem., 131, 10.1016/j.bioorg.2022.106327 · DOI
  138. Qi, 2021, Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein, Bioorg. Chem., 111, 10.1016/j.bioorg.2021.104901 · DOI · Paper page
  139. Marcellino, 2023, An MDM2 degrader for treatment of acute leukemias, Leukemia, 37, 370, 10.1038/s41375-022-01735-6 · DOI
  140. Chen, 2022, Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression, Theranostics, 12, 6665, 10.7150/thno.75444 · DOI
  141. Cui, 2023, Synthesis and Antineoplastic Activity of a Dimer, Spiroindolinone Pyrrolidinecarboxamide, Molecules, 28, 10.3390/molecules28093912 · DOI
  142. Dong, 2009, Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway, Mol. Cancer, 8, 103, 10.1186/1476-4598-8-103 · DOI · Paper page
  143. Kogan-Sakin, 2011, Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells, Cell Death Differ., 18, 271, 10.1038/cdd.2010.94 · DOI
  144. Kong, 2023, Selective degradation of the p53-R175H oncogenic hotspot mutant by an RNA aptamer-based PROTAC, Clin. Transl. Med, 13, 10.1002/ctm2.1191 · DOI
  145. Chang, 2022, MDM2-BCL-X(L) PROTACs enable degradation of BCL-X(L) and stabilization of p53, Acta Mater. Med, 1, 333
  146. Armata, 2007, The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression, Cancer Res, 67, 11696, 10.1158/0008-5472.CAN-07-1610 · DOI
  147. Koyama, 2023, Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study, Cancer Discov., 13, 1814, 10.1158/2159-8290.CD-23-0419 · DOI
  148. Gounder, 2023, A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas, J. Clin. Oncol., 41, 1714, 10.1200/JCO.22.01285 · DOI
  149. LoRusso, 2023, The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study, Cancer Discov., 13, 1802, 10.1158/2159-8290.CD-23-0153 · DOI · Paper page
  150. Mascarenhas, 2022, The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study, Blood Adv., 6, 1162, 10.1182/bloodadvances.2021006043 · DOI
  151. Yan, 2021, A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity, Theranostics, 11, 6833, 10.7150/thno.59020 · DOI
  152. Billimoria, 2023, Senescence in cancer: Advances in detection and treatment modalities, Biochem Pharm., 215, 10.1016/j.bcp.2023.115739 · DOI
  153. Troiani, 2022, Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer, Nat. Commun., 13, 2177, 10.1038/s41467-022-29824-1 · DOI
  154. Eberhart, 2023, Killing zombies: Senolytic therapy in pilocytic astrocytoma, Neuro Oncol., 25, 748, 10.1093/neuonc/noad016 · DOI
  155. Carpenter, 2021, Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy, Biochem Pharm., 193, 10.1016/j.bcp.2021.114765 · DOI
  156. Sasaki, 2020, FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer, Cancers (Basel), 12, 10.3390/cancers12102976 · DOI
  157. Chang, 2024, Senolysis Enabled by Senescent Cell-Sensitive Bioorthogonal Tetrazine Ligation, Angew. Chem. Int Ed. Engl., 63, 10.1002/anie.202315425 · DOI
  158. Toufektchan, 2018, The Guardian of the Genome Revisited: p53 Downregulates Genes Required for Telomere Maintenance, DNA Repair, and Centromere Structure, Cancers (Basel), 10, 10.3390/cancers10050135 · DOI
  159. Horikawa, 2011, p53 governs telomere regulation feedback too, via TRF2, Aging (Albany NY), 3, 26, 10.18632/aging.100271 · DOI
  160. Chou, 2022, Sirtuin-1 attenuates cadmium-induced renal cell senescence through p53 deacetylation, Ecotoxicol. Environ. Saf., 245, 10.1016/j.ecoenv.2022.114098 · DOI
  161. Yang, 2019, Sirtuin 2 expression suppresses oxidative stress and senescence of nucleus pulposus cells through inhibition of the p53/p21 pathway, Biochem Biophys. Res Commun., 513, 616, 10.1016/j.bbrc.2019.03.200 · DOI
  162. Solary, 2022, Ageing and cancer: a research gap to fill, Mol. Oncol., 16, 3220, 10.1002/1878-0261.13222 · DOI
  163. Carroll, 2022, Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care, Nat. Rev. Clin. Oncol., 19, 173, 10.1038/s41571-021-00580-3 · DOI

Cited by

See all 94

Metadata

Authors
Huang, Y., Che, X., Wang, P. W., & Qu, X.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2024-06
Volume
101
Pages
44-57
ISSN
1044-579X
Cited by
94
References
43
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: p53/MDM2 signaling pathway in aging, senescence and tumorigenesis. https://app.cochat.ai/papers/10.1016/j.semcancer.2024.05.001
The paper
Huang, Y., Che, X., Wang, P. W., & Qu, X. (2024). p53/MDM2 signaling pathway in aging, senescence and tumorigenesis. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2024.05.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.